Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 20 Dec 2024
In randomized study, ensartinib doubled PFS versus first-generation ALK inhibitor
Read Full News1.
Study finds higher breast cancer rates in areas with more air pollution
2.
Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects
3.
When Healthcare Chatbots Fall Short of Human Connection
4.
Taking vitamin D daily decreased cancer mortality, according to a study.
5.
'It's rare and it's scary.' Dark spot on your fingernail could mean cancer
1.
Genetic Screening: A Game Changer in Cancer Prevention
2.
Unlocking the Benefits of Eltrombopag: A Comprehensive Guide
3.
Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself
4.
The Latest Advances in Glioblastoma Treatment and Prevention
5.
A Review on Genetic Predispositions and Clinical Advancements of Multiple Myeloma Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
3.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
5.
Thromboprophylaxis In Medical Settings- An Update
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge